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ANTIBODIES FROM PATIENTS WITH 
RHEUMATOID ARTHRITIS AND 
SYSTEMIC LUPUS ERYTHEMATOSUS RECOGNIZE 
DIFFERENT EPITOPES OF A SINGLE 
HETEROGENEOUS NUCLEAR RNP CORE PROTEIN 
Possible Role of Cross-Reacting Antikeratin Antibodies 
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ANTONELLA CERINO, MARC0 BESTAGNO, FABIO COBIANCHI, 
and GIULIA C. B. ASTALDI-RICOTTI 
Antibodies to recombinant heterogeneous nu- 
clear RNP core protein A1 were detected in sera from 27 
of 58 patients with rheumatoid arthritis (RA) and from 
7 of 31 patients with systemic lupus erythematosus, by 
immunoblotting and enzyme-linked immunosorbent as- 
say. Protein A1 consists of 2 distinct domains: The 
N-terminal sequence is identical to a single-stranded 
DNA binding protein termed UP1, and the Ckerminal 
domain shows a partial homology with keratin. All 7 
Al-positive systemic lupus erythematosus sera reacted 
with UP1, whereas 9 of the 27 Al-positive RA sera did 
not. In RA, anti-A1 activity was significantly associated 
with antikeratin antibodies (AKA); these antibodies 
were present in 23 of 27 Al-positive sera and 10 of 31 
Al-negative sera (P < 0.01). Immunoabsorption with 
recombinant protein A1 resulted in a significant reduc- 
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tion of AKA titers in 6 of 10 RA sera tested, suggesting 
that AKA from RA patients may cross-react with the 
C-terminal portion of the heterogeneous nuclear RNP 
protein Al. 
Antibodies to heterogeneous nuclear ribo- 
nucleoprotein (hnRNP) particles have been found in 
patients with mixed connective tissue disease (MCTD) 
( l ) ,  but little is known about the autoantigenic prop- 
erties of the individual peptides involved. In eukary- 
otic cells, preprocessed messenger RNA (hnRNA) are 
found associated with proteins to form hnRNP parti- 
cles. The majority of the protein component is repre- 
sented by a family of structurally related polypeptides 
(hnRNP core proteins), which are basic in charge and 
rich in the amino acid glycine; these core proteins have 
been suggested to play a role in RNA splicing (2). One 
of the main constituents of hnRNP core proteins is a 
34-kd protein termed Al .  As recently revealed by 
complementary DNA (cDNA) cloning, this protein 
consists of 2 distinct domains with different structures 
(3). The N-terminal domain (residues 2-196) has a 
sequence identical to that reported for a single- 
stranded DNA binding protein previously termed UP1 
(4). The C-terminal portion is a glycine-rich polypep- 
tide that shows a partial homology with human epider- 
mal keratin (3,4). 
In recent studies, the use of purified protein A1 
obtained by recombinant DNA techniques has allowed 
detection of autoantibodies directed toward this pro- 
tein. Anti-A1 antibodies have been found in 23% and 
37% of systemic lupus erythematosus (SLE) patients 
in 2 different studies (5,6). Furthermore, antibodies 
reacting with protein A1 were found in sera from 
patients with adult-onset rheumatoid arthritis (RA) (5 )  
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and patients with juvenile arthritis (6). Results of the 
present study indicate that antibodies from patients 
with SLE and R A  may react with different epitopes of 
protein A1 and that cross-reacting antikeratin antibod- 
ies (AKA) may partially account for  anti-A1 activity in 
RA sera. 
PATIENTS AND METHODS 
Patients. Serum samples were obtained from 31 pa- 
tients (27 women and 4 men) with SLE, as defined by the 
American Rheumatism Association (ARA) 1982 revised cri- 
teria (7), and 58 patients (47 women and 11 men) with RA, as 
defined by the ARA 1987 revised criteria (8). The mean age 
of the SLE patients was 36 years (range 16-62) and that of 
the RA patients was 45 (range 1673). Twenty-five healthy 
volunteers (20 women and 5 men) were studied as a control 
group; their mean age was 42 (range 21-63). Informed 
consent was obtained from all subjects. 
Antigen purification procedure. Heterogeneous nu- 
clear RNP core protein A1 was overexpressed as unfused 
34-kd protein in Escherichia coli harboring a recombinant 
expression vector (pRC23) that carries the A1 cDNA coding 
sequence (3). For the expression of the N-terminal domain 
(UPl), the C-terminal portion of A1 cDNA was removed 
from the original plasmid using appropriate restriction endo- 
nucleases, and the truncated product was inserted into 
pRC23 as previously described (9). The expression of recom- 
binant proteins A1 and UP1 was determined by Coomassie 
blue staining of sodium dodecyl sulfate (SDS)-polyacryl- 
amide gels and by Western blot analysis. The recombinant 
proteins were purified by affinity column procedures as 
previously described (9), and the final preparations were 
found to be homogeneous by SDS-polyacrylamide gel elec- 
trophoresis and by amino acid sequencing. 
Rabbit antibodies against hnRNP A1 protein. A New 
Zealand white rabbit was injected intramuscularly, 6 times, 
at 15-day intervals, with 200 pg of recombinant hnRNP 
protein A1 in 0.5 ml of sterile saline solution plus 0.5 ml of 
Freund's adjuvant (complete for the first immunization and 
incomplete for the following immunizations) (10). The final 
titer of anti-A1 antibody was 1:500,OOO, as determined by 
enzyme-linked immunosorbent assay (ELISA). 
Immunoblotting technique. Four micrograms of 
recombinant hnRNP A1 or 150 pg of crude nuclear extract 
from HeLa cells (1 1) was mixed in 62.5 mM Tris HCI, pH 
6.8, containing 5% 2-mercaptoethanol, 2% SDS, and 0.1% 
bromphenol blue, heated at 100°C for 5 minutes, and then 
centrifuged. The supernatant was loaded on a 10% SDS- 
polyacrylamide gel and run at 30 mA for 4 hours. The gel was 
blotted onto nitrocellulose as described by Towbin e t  al(l2). 
The nitrocellulose sheet was cut into strips, washed exten- 
sively, and processed as described previously (13). 
ELISA. Serum antibodies reacting with protein A1 
and UP1 peptide were detected and quantitated by ELISA as 
previously described (14). Briefly, the purified protein was 
diluted at 2 pglrnl in 50 mM carbonate buffer, pH 9.6, plated 
(100 pl/well), and incubated at 4°C overnight. Plates were 
then blocked with 10% fetal calf serum in phosphate buffered 
saline (PBS), washed in PBS-Tween 20, and incubated for 2 
hours with patient sera diluted 1: 100. After additional wash- 
ings, plates were incubated for 2 hours with peroxidase- 
conjugated antibodies to all human Ig classes (rabbit anti- 
human IgA, IgM, IgG, K ,  A;  Dakopatts, Copenhagen, 
Denmark), washed, and exposed to the substrate solution as 
described (14). 
The optical density (OD) was measured at 492 nm, 
using a Titertek multiscan reader (Flow Laboratories, Op- 
era, Italy). Values more than 3 standard deviations above the 
mean in normal controls were considered positive. In a 
previously reported study, all but 1 patient serum with OD 
above this value were shown to react with purified protein 
A1 by immunoblotting assays, while no patient sera with 
lower values reacted with this protein, nor did any control 
serum (5). 
Immunoabsorption. Two hundred micrograms of pu- 
rified recombinant protein A1 was diluted in 200 pl of patient 
serum (diluted 1:s in 150 mmoleshter PBS, pH 7.5) for 2 
hours at room temperature, then incubated overnight at 4°C. 
After incubation, the samples were centrifuged at 13,000g 
for 20 minutes at 4"C, and the supernatant was tested by 
immunofluorescence for the presence of autoantibodies. 
Immunofluorescence studies. AKA in patient sera 
were detected by immunofluorescence on human epidermis 
from skin biopsy samples that had been obtained for lupus 
band testing or other immunofluorescence studies and had 
been found to be normal. Unfixed, 5 pm-thick cryostatic 
sections were mounted onto glass slides, incubated for 30 
minutes with patient serum diluted in PBS, and washed 3 
times in PBS. Fluorescein-conjugated rabbit anti-human Ig 
antibodies were then added for 20 minutes, prior to 3 
additional washings in PBS. To exclude the possibility of in 
vivo binding of autologous antibodies, a negative control, 
using PBS alone instead of patient serum, was routinely 
tested along with each skin biopsy. Distinguishable epider- 
mal fluorescence at a serum dilution of r l : 1 0  was consid- 
ered positive. No detectable fluorescence was found in 
controls. Positive samples showed a laminar fluorescence 
pattern (15) similar to that obtained using a monoclonal 
mouse anti-human keratin antibody (Dako-Keratin; 
Dakopat ts). 
Antinuclear antibodies (ANA) were detected by im- 
munofluorescence on cultured HEp-2 cells, and antibodies 
to double-stranded DNA (anti-dsDNA) were detected using 
commercially available Crithidia Iuciliae preparations (Delta 
Biologicals, Pomezia, Italy). ANA and anti-dsDNA were 
considered positive when titers were r l : 80  and zl:lO, 
respectively. 
Statistical analysis. The frequency distributions of 
various autoantibodies in anti-Al-positive patients and anti- 
Al-negative patients were compared by chi-square and 
Fisher's exact test. 
RESULTS 
Detection and quantitation of anti-A1 antibodies. 
Human sera were tested for binding to protein A1 in 
immunoblot assays using a purified antigen prepara- 
tion (Figure 1A). Sera reacting with purified protein in 
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Figure 1. Detection of antibodies to heterogeneous nuclear RNP (hnRNP) core protein A1 by 
immunoblotting assays. A, Binding of human sera to purified recombinant protein. Lanes 1 4 ,  
rheumatoid arthritis (RA) sera; lanes 5-8, systemic lupus erythematosus (SLE) sera; lanes 9-12, 
control sera. B, Binding of human sera to hnRNP core protein A1 present in crude nuclear 
extract, as compared with rabbit anti-A1 antibodies. Lanes 1 and 16, rabbit anti-A1 antibody; 
lanes 2 , 6 ,  8, 11, and 15, positive RA sera; lanes 7 and 14, negative RA sera; lanes 3, 9, 12, and 
13, positive SLE sera; lane 10, negative SLE serum; lanes 4 and 5 ,  control sera. The second 
antibody was directed to rabbit Ig in lanes 1 and 16, and to all human Ig classes in lanes 2-15. 
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Figure 2. Binding of rheumatoid arthritis (R.A.) and systemic lupus 
erythematosus (S.L.E.) patient sera and normal control sera to 
purified recombinant heterogeneous nuclear core protein A I ,  as 
determined by enzyme-linked immunosorbent assay. Optical den- 
sity (O.D.) was measured at 492 nm. Shaded area represents the 
range of values considered negative. 
this assay were also found to bind protein A1 in 
immunoblot assays using crude nuclear extract (Figure 
1B). None of the normal control sera reacted with 
purified recombinant protein or protein A1 in crude 
nuclear extract. 
The same purified antigen preparation used for 
immunoblotting was used in the ELISA. Positive 
values were found in 7 of the SLE patients (23%) and 
in 27 of the RA patients (47%). RA sera showed the 
highest binding values (Figure 2). 
Binding to the N-terminal domain (UP1). To 
further characterize the antibody specificity in SLE 
and RA patients, all Al-positive sera were tested, by 
ELISA, for selective binding to the N-terminal region 
(UP1). All of the Al-positive SLE sera showed a 
strong reaction with the UP1 peptide, while 9 of 27 
Al-positive RA sera did not. The level of UP1 binding 
was generally higher in the SLE sera (Figure 3). 
Association with ANA and AKA. Binding to A1 
correlated with ANA and AKA positivity in patients 
with rheumatoid arthritis, but no relationship was 
found between anti-A1 and rheumatoid factor. In SLE 
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Figure 3. Binding of anti-Al-positive patient sera and normal con- 
trol sera to the N-terminal region of recombinant hnRNP core 
protein A1 (UPl): See Figure 2 for definitions. 
patients, no correlation was found between anti-A1 
and any of the other antibodies tested (Table 1). 
To determine the role of anti-A1 antibodies in 
ANA-positive RA, ANA titers in 10 ANA-positive 
sera were measured before and after immunoabsorp- 
tion with purified recombinant protein Al .  None of the 
sera showed a significant change in ANA titer follow- 
ing immunoabsorption. The same procedure was used 
to determine whether AKA cross-react with hnRNP 
protein Af.  Six of 10 anti-Al-positive sera had a 
Table 1. Frequency distribution of antinuclear antibodies, antiker- 
atin antibodies, anti-double-stranded DNA, and rheumatoid factor 
according to the presence or absence of anti-A1 antibodies* 
SLE patients RA patients 
ANA AKA Anti-dsDNA ANA AKA RFt  
Anti-Al+ 717 117 3fl  19/27 23/27 23/27 
Anti-A1- 24/24 3/24 11/24 8/31 10131 21/31 
P NS NS NS <0.01 <0.01 NS 
* SLE = systemic lupus erythematosus; ANA = antinuclear anti- 
bodies; AKA = antikeratin antibodies; anti-dsDNA = anti- 
double-stranded DNA; RA = rheumatoid arthritis; R F  = rheuma- 
toid factor; EJS = not significant. 
t By latex fixation. 
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Figure 4. Immunoabsorption of an anti-A I-positive rheumatoid arthritis serum with recombinant 
heterogeneous nuclear RNP core protein A1 . A, Before immunoabsorption, bright fluorescent staining 
of the outer epidermal layer (demonstrating antikeratin antibodies), associated with nuclear staining 
(antinuclear antibodies), is seen. B, After immunoabsorption, there is selective disappearance of 
antikeratin antibodies. 
detectable decrease in AKA titer after immunoabsorp- 
tion with recombinant protein A1 (Figures 4 and 5). 
The AKA titer decreased in all of the anti-Al-positive 
sera that were negative for anti-UP1 binding, and in 
only 1 of 5 sera that reacted with UP1 (Figure 5).  
DISCUSSION 
Our results show that sera from patients with 
SLE and RA do react with hnRNP protein Al.  Anti- 
bodies from SLE patients are specific for the N- 
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Figure 5. Changes in antikeratin antibody (AKA) titers in 10 anti- 
A 1-positive rheumatoid arthritis sera after immunoabsorption with 
purified recombinant heterogeneous nuclear RNP core protein A I .  
W = sera with positive UP1 binding. G = sera with negative UP1 
binding. 
terminal domain, which has a sequence identical to 
that of a previously identified DNA binding protein (41, 
whereas R A  sera bind either the N-terminal or the 
C-terminal domain, the latter of which is structurally 
related to human epidermal keratin (3,4). Cross- 
reacting antikeratin antibodies, often found in RA sera 
(15,161, can partially account for the high frequency of 
anti-A1 reactivity in these cases. 
In a study by Fritzler et al ( I ) ,  sera from 
patients with MCTD were found to react with an 
hnRNP/RNA antigen, but no data were given about 
any specific polypeptide involved in anti-hnRNP auto- 
immunity. In our previous studies ( 5 ) ,  sera from 
patients with connective tissue diseases were shown to 
react with purified recombinant hnRNP protein Al. In 
the present study, we found that sera from patients 
with SLE and RA also react with protein A1 present in 
crude nuclear extract. These findings strongly support 
the view that protein A1 can be an important autoan- 
tigenic structure within the hnRNP complex (6). 
The use of purified recombinant antigens offers 
a great advantage for studying autoantibody specificity 
and may enable the  identification of cross-reactivity 
with other proteins because of structural homology of 
different molecules (6,16). We used this approach in 
the present study to further characterize anti-A1 anti- 
bodies in 2 different autoimmune conditions, SLE and 
RA. In SLE, anti-A1 antibodies react with the N- 
terminal (UPl) domain. Since UP1 peptide binds DNA 
(4,17). as do anti-DNA antibodies, our data further 
support the hypothesis described by Jensen et al 
(6), that anti-A1 antibodies may be involved in the 
idiotype-antiidiotype network of anti-DNA antibod- 
ies. Studies on the biologic significance and clinical 
relevance of anti-UP1 antibodies in SLE and related 
conditions are now in progress. 
A very high frequency of anti-A1 antibodies 
was found in RA. The majority of Al-positive RA 
patients also displayed positive ANA. but our immu- 
noabsorption results demonstrated that ANA positiv- 
ity was not due to anti-A1 antibodies. A1 protein is 
easily degradable (17). and it could be lost during the 
cell fixation procedure for the ANA fluorescence test. 
However, immunoblotting results suggest that anti-A1 
antibodies are frequently associated with other auto- 
antibodies to nuclear antigens, e.g., histones (Figure 
I ) ,  which may account for the high frequency of ANA 
positivity in these patients. 
In contrast to SLE sera, a significant percent- 
age of RA sera with anti-A1 reactivity did not recog- 
nize UPl. This may be evidence in support of the 
following hypotheses: 1) Since A l  protein is easily 
degraded in vivo (17), different determinants ex- 
pressed by degradation may be immunogenic in dif- 
ferent conditions (6). 2) Since epidermal keratin and 
the C-terminal domain of the A1 protein show a partial 
sequence homology (3,4), anti-A1 activity in RA may 
be partially due to cross-reacting AKA ( 5 ) .  
It is well known that more than 50% of all 
patients with RA have circulating AKA (18). We have 
shown that anti-A1 antibodies are often associated 
with AKA detected by immunofluorescence assays on 
human skin. Furthermore, a marked reduction in 
antikeratin activity is found following immunoabsorp- 
tion with purified protein Al. I t  is noteworthy that 
significant reductions in the AKA titer occurred 
mainly in those sera that reacted with A1 but not with 
UPI. This spggests that AKA can actually bind the 
C-terminal domain of protein A 1. 
In conclusion, our results indicate that AKA 
from RA patients may react with a protein belonging to 
the hnRNP particle, i.e., the A1 protein, which is 
largely expressed in human nuclei (2.4). A different 
epitope of the same protein is also recognized by other 
autoantibodies, which are mainly present in SLE. 
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